Vital KSK Holdings, Inc. (TYO:3151)
1,374.00
+1.00 (0.07%)
Feb 16, 2026, 3:30 PM JST
Vital KSK Holdings Revenue
Vital KSK Holdings had revenue of 164.32B JPY in the quarter ending December 31, 2025, with 0.44% growth. This brings the company's revenue in the last twelve months to 604.24B, up 0.83% year-over-year. In the fiscal year ending March 31, 2025, Vital KSK Holdings had annual revenue of 600.37B with 2.19% growth.
Revenue (ttm)
604.24B
Revenue Growth
+0.83%
P/S Ratio
0.11
Revenue / Employee
160.87M
Employees
3,756
Market Cap
66.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
| Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
| Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
| Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
| Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.46T |
| Otsuka Holdings | 2.47T |
| Chugai Pharmaceutical | 1.26T |
| HOYA Corporation | 915.21B |
| ASKA Pharmaceutical Holdings | 68.70B |
| Software Service | 42.30B |
| Shofu | 38.97B |
| Medley | 36.79B |